ArticleJournal of ovarian research2026
CircRNA14781 promotes olaparib resistance of ovarian cancer cells by regulating miR-330-5p/NGFR pathway.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundOlaparib resistance is an inevitable clinical challenge for ovarian cancer treatment, and the heterogeneity of drug resistance requires the development of more potential targets to collaboratively overcome the resistance. The present study aimed to uncover the role of circular RNA (circRNA) involved in olaparib resistance.
methodsUWB1.289 (UWB) and PEO1 cells carrying BRCA1/2 mutation were induced to establish olaparib-resistant cells (UWB-OR and PEO1-OR). Whole-transcriptome analysis was performed to identify differentially expressed circRNAs (DECs) and genes (DEGs) in the resistant cell lines. Candidate DEG and DEC were screened using bioinformatics analysis, circRNA-miRNA-mRNA regulatory network, and quantitative polymerase chain reaction. The malignant biological behavior of cells was assessed using cell biological function assays. A dual-luciferase reporter assay was conducted to evaluate the binding ability between RNAs.
resultsThe resistant cells exhibited enhanced proliferation, colony-forming and DNA repair abilities in the condition supplemented with olaparib. Ninety-seven DECs and 190 DEGs were screened in resistant cell lines. The ceRNA network covered four upregulated DEGs and eight upregulated DECs. circRNA14781 and nerve growth factor receptor (NGFR) levels were both upregulated, and miR-330-5p levels decreased in UWB-OR and PEO1-OR. Overexpression of circRNA14781 promoted olaparib resistance and enhanced colony-forming and migratory abilities of UWB and PEO1 cells, which were then reversed by co-overexpression of miR-330-5p. Knockdown of circRNA14781 enhanced the sensitivity to olaparib and weakened the resistant phenotype of UWB-OR and PEO1-OR cells, and the simultaneous inhibition of miR-330-5p offset these changes. miR-330-5p could bind with circRNA14781 and NGFR in vitro. Co-overexpression of NGFR in resistant cells restored the drug-resistance, proliferation, colony-forming, migratory, and DNA repair abilities weakened by miR-330-5p overexpression. Furthermore, knockdown of NGFR enhanced the drug-sensitivity, and suppressed these abilities of the resistant cells.
conclusioncircRNA14781 promoted olaparib resistance in ovarian cancer cells by sponging miR-330-5p and upregulating NGFR. circRNA14781 and NGFR could be the potential targets to overcome olaparib resistance in ovarian cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.